Faster global financial news!
Novo Nordisk
-
Analysis: Novo Nordisk stock 'too cheap to ignore' after 66%+ drop from 2024 high, despite Eli Lilly GLP-1 competition
The Motley Fool analysis suggests that after Novo Nordisk's stock declined over 66% from its 2024 high, traditional valuation metrics like price-to-sales (4x vs 5-year average 8.6x) and price-to-earni
-
Denmark raises 2026 economic growth forecast for fourth time, mainly boosted by Novo Nordisk's weight-loss drug Wegovy
Denmark raises 2026 economic growth forecast for fourth time, mainly boosted by Novo Nordisk's weight-loss drug Wegovy
-
Deutsche Bank downgrades Ozempic maker Novo Nordisk to sell after 70% stock-price dive from peak
Deutsche Bank downgrades Ozempic maker Novo Nordisk to sell after 70% stock-price dive from peak
-
Eli Lilly's Q2 revenue grew by 48%, and it plans to submit a BLA for its weight-loss drug Retatrutide in Q1 2027; Novo Nordisk, on the other hand, laid off 12,000 employees.
Eli Lilly reported a 48% increase in Q2 2026 revenue and raised its full-year guidance. Its weight-loss drugs, Mounjaro and Zepbound, generated a combined $14.9 billion in sales in Q2, capturing appro
-
Eli Lilly (LLY) stock rose 3.37% to $1223.04, narrowing the early lead of Novo Nordisk in the weight-loss drug market.
Eli Lilly's stock price has rebounded from its 50-day moving average and is currently above its 21-day and 10-day moving averages, demonstrating strong market performance. The company is challenging N
-
Novo Nordisk stock falls after Wegovy pill's 'surprise miss', despite improved full-year outlook
Novo Nordisk stock falls after Wegovy pill's 'surprise miss', despite improved full-year outlook
-
Weight Loss Drug Stocks Novo Nordisk, Eli Lilly Slump Below Key Levels
Weight Loss Drug Stocks Novo Nordisk, Eli Lilly Slump Below Key Levels
-
Novo Nordisk's stock slumped after announcing a Phase 3 trial failure.
Novo Nordisk's stock slumped after announcing a Phase 3 trial failure.
-
Analysis: Novo Nordisk's New Weight-Loss Drugs Face Efficacy Challenges Against Eli Lilly
A recent analysis indicates that Novo Nordisk's stock has fallen 29% over the past 12 months, as its new weight-loss drug candidates face stiff competition from Eli Lilly. Novo Nordisk's CagriSema, a
-
Analysis: Novo Nordisk stock 'too cheap to ignore' after 66%+ drop from 2024 high, despite Eli Lilly GLP-1 competition
The Motley Fool analysis suggests that after Novo Nordisk's stock declined over 66% from its 2024 high, traditional valuation metrics like price-to-sales (4x vs 5-year average 8.6x) and price-to-earni
-
Denmark raises 2026 economic growth forecast for fourth time, mainly boosted by Novo Nordisk's weight-loss drug Wegovy
Denmark raises 2026 economic growth forecast for fourth time, mainly boosted by Novo Nordisk's weight-loss drug Wegovy
-
Deutsche Bank downgrades Ozempic maker Novo Nordisk to sell after 70% stock-price dive from peak
Deutsche Bank downgrades Ozempic maker Novo Nordisk to sell after 70% stock-price dive from peak
-
Eli Lilly's Q2 revenue grew by 48%, and it plans to submit a BLA for its weight-loss drug Retatrutide in Q1 2027; Novo Nordisk, on the other hand, laid off 12,000 employees.
Eli Lilly reported a 48% increase in Q2 2026 revenue and raised its full-year guidance. Its weight-loss drugs, Mounjaro and Zepbound, generated a combined $14.9 billion in sales in Q2, capturing appro
-
Eli Lilly (LLY) stock rose 3.37% to $1223.04, narrowing the early lead of Novo Nordisk in the weight-loss drug market.
Eli Lilly's stock price has rebounded from its 50-day moving average and is currently above its 21-day and 10-day moving averages, demonstrating strong market performance. The company is challenging N
-
Novo Nordisk stock falls after Wegovy pill's 'surprise miss', despite improved full-year outlook
Novo Nordisk stock falls after Wegovy pill's 'surprise miss', despite improved full-year outlook
-
Weight Loss Drug Stocks Novo Nordisk, Eli Lilly Slump Below Key Levels
Weight Loss Drug Stocks Novo Nordisk, Eli Lilly Slump Below Key Levels
-
Novo Nordisk's stock slumped after announcing a Phase 3 trial failure.
Novo Nordisk's stock slumped after announcing a Phase 3 trial failure.
-
Analysis: Novo Nordisk's New Weight-Loss Drugs Face Efficacy Challenges Against Eli Lilly
A recent analysis indicates that Novo Nordisk's stock has fallen 29% over the past 12 months, as its new weight-loss drug candidates face stiff competition from Eli Lilly. Novo Nordisk's CagriSema, a
- No data
Novo Nordisk
24H Trending
-
1
Aethir (ATH) Token Value Analysis: Decentralized Cloud Computing Project Potential and Risk Assessment
-
2
Bitcoin rises above $77,000, bucking tech selloff driven by AI safety concerns and rising oil prices
-
3
Guyana's President: Oil Revenue Surges Due to Iran Conflict
-
4
NOAH Coin Analysis: Distinguishing Between Controversial Projects and Active Payment Infrastructure
-
5
RIKEN Coin Value Analysis: Numerous Projects Share the Same Name, What's Its Investment Potential?
-
6
FXBK Coin Analysis: What Is It? Is It Worth Investing In?
-
7
Cosco Shipping Heavy Industry Completes China IPO Guidance Registration
-
8
Beginner's Guide to Bitcoin Trading: A Comprehensive Analysis of Security Risks and Prevention Strategies
-
9
Taiwan to open second quasi-diplomatic mission in the Philippines, sources say
-
10
Samsung Display develops world's first 6.9-inch mobile OLED panel with 2K resolution, 165Hz refresh rate, and 30% lower power consumption
Markets Today
Recommended Reading
Hot Topics
Svmuu focuses on blockchain industry trends and cutting-edge cryptocurrency news, while also covering real-time market data and in-depth analysis of the Hong Kong, U.S., and foreign exchange markets. Here, you can not only access professional 24/7 news updates and accurate market data, but also utilize practical investment tools to help you capitalize on opportunities in both digital assets and traditional financial markets. Whether you are a blockchain enthusiast or an investor in Hong Kong, U.S., or foreign exchange markets, we provide efficient and timely information services to empower your investment decisions.
- User Agreement
- Privacy Policy
- Contact Us
- Business Partnerships
- Disclaimer
- Content Statement
- About Us
- Sitemap
Coming Soon!
